智通财经APP获悉，维亚生物(01873)一度跌超10%，截至发稿，跌7.37%，报1.445港元，成交额1273.62万港元。
消息面上，维亚生物发布2026年中期业绩，今年上半年，公司实现收益10.065亿元，同比增加20.99%；净利润1.009亿元，同比减少32.1%；经调整非国际财务报告准则净利润1.28亿元，同比减少30.08%。公司指，这主要归因于报告期内投资收益的贡献下降、外汇汇率变动的不利影响以及布局新业务所带来的研发费用的增加。
上半年，公司CRO业务收入由去年同期的4.23亿元下降至4.05亿元，降幅约为4.2%；对应经调整毛利由去年同期的1.95亿元下降至1.74亿元，降幅约为10.7%。但剔除外汇汇率变动的不利影响之后，恒定汇率之下的CRO业务收入同比下降约为1.2%，经调整毛利同比下降约为2.6%。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.